Seung Yun Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seung Yun Kim has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Seung-Hee Seo
질병관리청 의료안전예방국 항생제내성관리
3 shared publications - 나리 신
질병관리청 의료안전예방국 항생제내성관리
3 shared publications - Eun Kyoung Kim
Division of Disease Control Capacity Building, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea
2 shared publications 신영 이
질병관리청 의료안전예방국 항생제내성관리
2 shared publications- Dosang Lim
Adverse Event Management Team, Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea
1 shared publication - Enhi Cho
Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea
1 shared publication
Latest Publications
- Open Access
- 27 May 2025
- Published by Korea Disease Control and Prevention Agency (Public Health Weekly Report) in Public Health Weekly Report
- Vol. 18 (26) , 955-973
2023년 국내 급성상기도감염 및 하기도감염 항생제 처방률 등급 및 2020–2023년 등급 변화 추이
이신영, 서승희, 김승연, 신나리. Public Health Weekly Report 2025;18:955-73. https://doi.org/10.56786/PHWR.2025.18.26.1
- 27 May 2025
- Published by Korea Disease Control and Prevention Agency (Public Health Weekly Report) in Public Health Weekly Report
- Vol. 18 (26) , 955-973
Open Access2023년 국내 급성상기도감염 및 하기도감염 항생제 처방률 등급 및 2020–2023년 등급 변화 추이
이신영, 서승희, 김승연, 신나리. Public Health Weekly Report 2025;18:955-73. https://doi.org/10.56786/PHWR.2025.18.26.1
- Open Access
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (2) , 203-214
Korea’s National Action Plan on Antimicrobial Resistance: Focusing on the Appropriate Use of Antibiotics
Jeong YI, et al. Infect Chemother. 2025 May;57:e35. https://doi.org/10.3947/ic.2025.0028
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (2) , 203-214
Open AccessKorea’s National Action Plan on Antimicrobial Resistance: Focusing on the Appropriate Use of Antibiotics
Jeong YI, et al. Infect Chemother. 2025 May;57:e35. https://doi.org/10.3947/ic.2025.0028
- Open Access
- 24 December 2024
- Published by Korea Disease Control and Prevention Agency (Public Health Weekly Report) in Public Health Weekly Report
- Vol. 18 (5) , 225-243
국내 요양병원의 항생제 사용 실태 분석
이신영, 김용찬, 김동숙, 서승희, 김승연, 신나리. Public Health Weekly Report 2025;18:225-43. https://doi.org/10.56786/PHWR.2025.18.5.1
- 24 December 2024
- Published by Korea Disease Control and Prevention Agency (Public Health Weekly Report) in Public Health Weekly Report
- Vol. 18 (5) , 225-243
Open Access국내 요양병원의 항생제 사용 실태 분석
이신영, 김용찬, 김동숙, 서승희, 김승연, 신나리. Public Health Weekly Report 2025;18:225-43. https://doi.org/10.56786/PHWR.2025.18.5.1
- Open Access
- 15 October 2023
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 66 (10) , 415-423
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea
As of June 2022, 5 coronavirus disease 2019 (COVID-19) vaccine brands have been used in Korea’s national immunization program. The Korea Disease Control and Prevention Agency has enhanced vaccine safety monitoring through a passive web-based reporting system and active text message-based monitoring. In this study, an enhanced safety monitoring system for COVID-19 vaccines is described and the frequencies and types of adverse events (AEs) associated with the 5 COVID-19 vaccine brands were analyzed. AE reports from the web-based COVID-19 Vaccination Management System and text message-based reports from recipients were analyzed. AEs were classified as nonserious or serious (e.g., death or anaphylaxis). The AE reporting rates were calculated based on the number of COVID-19 vaccine doses administered. A total of 125,107,883 doses were administered in Korea from February 26, 2021, to June 4, 2022. Among them, 471,068 AEs were reported, of which 96.1% were nonserious and 3.9% were serious. Among the 72,609 participants in the text message-based AE monitoring process, a higher AE rate of local and systemic reactions was reported for the 3rd versus 1st doses. A total of 874 cases of anaphylaxis (7.0 per 1,000,000 doses), 4 cases of thrombocytopenia syndrome (TTS), 511 cases of myocarditis (4.1 per 1,000,000 doses), and 210 cases of pericarditis (1.7 per 1,000,000 doses) were confirmed. Six fatalities were causally associated with COVID-19 vaccination (1 of TTS and 5 of myocarditis). Young adult age and female sex were related with a higher AE rate for COVID-19 vaccines. Most reported AEs were nonserious and of mild intensity.
- 15 October 2023
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 66 (10) , 415-423
Open AccessSafety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea
As of June 2022, 5 coronavirus disease 2019 (COVID-19) vaccine brands have been used in Korea’s national immunization program. The Korea Disease Control and Prevention Agency has enhanced vaccine safety monitoring through a passive web-based reporting system and active text message-based monitoring. In this study, an enhanced safety monitoring system for COVID-19 vaccines is described and the frequencies and types of adverse events (AEs) associated with the 5 COVID-19 vaccine brands were analyzed. AE reports from the web-based COVID-19 Vaccination Management System and text message-based reports from recipients were analyzed. AEs were classified as nonserious or serious (e.g., death or anaphylaxis). The AE reporting rates were calculated based on the number of COVID-19 vaccine doses administered. A total of 125,107,883 doses were administered in Korea from February 26, 2021, to June 4, 2022. Among them, 471,068 AEs were reported, of which 96.1% were nonserious and 3.9% were serious. Among the 72,609 participants in the text message-based AE monitoring process, a higher AE rate of local and systemic reactions was reported for the 3rd versus 1st doses. A total of 874 cases of anaphylaxis (7.0 per 1,000,000 doses), 4 cases of thrombocytopenia syndrome (TTS), 511 cases of myocarditis (4.1 per 1,000,000 doses), and 210 cases of pericarditis (1.7 per 1,000,000 doses) were confirmed. Six fatalities were causally associated with COVID-19 vaccination (1 of TTS and 5 of myocarditis). Young adult age and female sex were related with a higher AE rate for COVID-19 vaccines. Most reported AEs were nonserious and of mild intensity.
- Open Access
- 30 April 2023
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 14 (2) , 76-88
The incidence and clinical characteristics of myocarditis and pericarditis following mRNA-based COVID-19 vaccination in Republic of Korea adolescents from July 2021 to September 2022
Objectives: Age-specific information regarding myocarditis/pericarditis in adolescents following mRNA-based coronavirus disease 2019 (COVID-19) vaccination in Asia remains insufficient. This study investigated the incidence and clinical characteristics of myocarditis/pericarditis in Republic of Korea adolescents after mRNA-based COVID-19 vaccination.Methods: This retrospective descriptive study utilized patient data from the Korea Immunization Management System. Incidence rates were calculated according to age and sex. Clinical characteristics (symptoms/signs, laboratory values, and imaging results) were compared between mild and severe cases.Results: Between July 19, 2021 and September 30, 2022, 3,728,224 individuals aged 12 to 19 years received 6,484,165 mRNA-based COVID-19 vaccines, and 173 cases met the case definition for myocarditis/pericarditis: 151 mild (87.3%) and 22 severe (12.7%). The incidence was 3.8-fold higher in males than in females. Troponin I/ troponin T was elevated in 96% of myocarditis cases, demonstrating higher sensitivity than creatine kinase-myocardial band (67.6%) or C-reactive protein (75.2%). ST-segment or Twave on electrography abnormalities were found in 60.3% (85/141). Paroxysmal/sustained atrial/ventricular arrhythmias were more common in severe than in mild cases (45.5% vs. 16.8%, p=0.008). Edema on T2-weighted magnetic imaging occurred in 21.6% (8/37) and 62.5% (5/8) of mild and severe cases, respectively (p=0.03). Abnormal pericardial fluid collection or pericardial inflammation was found in 75.4% of pericarditis cases (49/65).Conclusion: Myocarditis/pericarditis occurred in rare cases following mRNA-based COVID-19 vaccination. Most cases were mild, but the incidence was higher in adolescent males and after the second dose. As bivalent severe acute respiratory syndrome coronavirus 2 mRNA vaccination started in Republic of Korea in October 2022, the post-vaccination incidence of myocarditis/pericarditis should be closely monitored, considering clinical characteristics.
- 30 April 2023
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 14 (2) , 76-88
Open AccessThe incidence and clinical characteristics of myocarditis and pericarditis following mRNA-based COVID-19 vaccination in Republic of Korea adolescents from July 2021 to September 2022
Objectives: Age-specific information regarding myocarditis/pericarditis in adolescents following mRNA-based coronavirus disease 2019 (COVID-19) vaccination in Asia remains insufficient. This study investigated the incidence and clinical characteristics of myocarditis/pericarditis in Republic of Korea adolescents after mRNA-based COVID-19 vaccination.Methods: This retrospective descriptive study utilized patient data from the Korea Immunization Management System. Incidence rates were calculated according to age and sex. Clinical characteristics (symptoms/signs, laboratory values, and imaging results) were compared between mild and severe cases.Results: Between July 19, 2021 and September 30, 2022, 3,728,224 individuals aged 12 to 19 years received 6,484,165 mRNA-based COVID-19 vaccines, and 173 cases met the case definition for myocarditis/pericarditis: 151 mild (87.3%) and 22 severe (12.7%). The incidence was 3.8-fold higher in males than in females. Troponin I/ troponin T was elevated in 96% of myocarditis cases, demonstrating higher sensitivity than creatine kinase-myocardial band (67.6%) or C-reactive protein (75.2%). ST-segment or Twave on electrography abnormalities were found in 60.3% (85/141). Paroxysmal/sustained atrial/ventricular arrhythmias were more common in severe than in mild cases (45.5% vs. 16.8%, p=0.008). Edema on T2-weighted magnetic imaging occurred in 21.6% (8/37) and 62.5% (5/8) of mild and severe cases, respectively (p=0.03). Abnormal pericardial fluid collection or pericardial inflammation was found in 75.4% of pericarditis cases (49/65).Conclusion: Myocarditis/pericarditis occurred in rare cases following mRNA-based COVID-19 vaccination. Most cases were mild, but the incidence was higher in adolescent males and after the second dose. As bivalent severe acute respiratory syndrome coronavirus 2 mRNA vaccination started in Republic of Korea in October 2022, the post-vaccination incidence of myocarditis/pericarditis should be closely monitored, considering clinical characteristics.